复方磺胺甲噁唑与万古霉素治疗医疗护理/呼吸机相关MRSA肺炎的病例对照研究
复方磺胺甲噁唑组42例,万古霉素组39例。万古霉素组30天死亡率和临床失败率显著更高,不良反应率两组相当。
要点
- 复方磺胺甲噁唑治疗MRSA肺炎在30天死亡率和临床失败率上优于万古霉素
- 倾向评分敏感性分析显示万古霉素30天死亡率54.1% vs 复方磺胺甲噁唑16.7%
- 两组不良反应发生率相当,但结论需大规模随机对照试验验证
核心结论
- 复方磺胺甲噁唑在治疗医疗护理/呼吸机相关MRSA肺炎方面似乎优于万古霉素。
主要发现
- 万古霉素组30天死亡率显著更高(多因素分析HR=5.28;95%CI=1.50-18.60;P<0.05)。
- 倾向评分敏感性分析中,万古霉素组30天死亡率为13/24(54.1%),复方磺胺甲噁唑组为4/24(16.7%),P<0.05。
- 万古霉素组临床失败率更高(23/39,59% vs 15/42,35.7%;P<0.05)。
- 倾向评分敏感性分析中,万古霉素组临床失败率为14/24(58.3%),复方磺胺甲噁唑组为6/24(25%),P<0.05。
- 两组不良反应发生率相当。
临床怎么用
- 对于医疗护理/呼吸机相关MRSA肺炎,复方磺胺甲噁唑可作为万古霉素的潜在替代选择。
局限性
- 本研究为回顾性病例对照研究,样本量较小,结论需大规模随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Therapeutic options available to treat MRSA pneumonia are limited. Trimethoprim/sulfamethoxazole is an attractive treatment because of its bactericidal anti-MRSA activity, oral and parenteral formulations and good penetration to the lung tissue. We aimed to compare the efficacy and safety of trimethoprim/sulfamethoxazole with vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia. METHODS: We carried out a retrospective case-control study of all consecutive hospitalized adult patients diagnosed with MRSA pneumonia at Beilinson Hospital during 2010-15 and treated with either vancomycin or trimethoprim/sulfamethoxazole. The primary outcomes were all-cause mortality at 30 days and clinical failure at the end of treatment. In order to reduce bias affecting the decision to use a specific antibiotic and as a sensitivity analysis, a propensity-score model for choosing between vancomycin and trimethoprim/sulfamethoxazole was used. RESULTS: We identified 42 patients with MRSA pneumonia treated with trimethoprim/sulfamethoxazole and 39 treated with vancomycin. There were no significant differences in the baseline characteristics between the groups. Vancomycin-treated patients showed significantly higher 30 day mortality on both multivariate analysis (HR = 5.28; 95% CI = 1.50-18.60; P < 0.05) and sensitivity analysis with propensity score [vancomycin 13/24 (54.1%) versus trimethoprim/sulfamethoxazole 4/24 (16.7%); P < 0.05], and higher clinical failure rates [vancomycin 23/39 (59%) versus trimethoprim/sulfamethoxazole 15/42 (35.7%); P < 0.05], also in the sensitivity analysis with propensity score [vancomycin 14/24 (58.3%) versus trimethoprim/sulfamethoxazole 6/24 (25%); P < 0.05]. The rates of side effects in both arms were comparable. CONCLUSIONS: Trimethoprim/sulfamethoxazole appears to be superior to vancomycin in the treatment of MRSA pneumonia. A large-scale randomized controlled trial is needed to evaluate these findings.
引用
- Eliakim-Raz N, Hellerman M, Yahav D, et al. Trimethoprim/sulfamethoxazole versus vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia: a case-control study. J Antimicrob Chemother. 2017. PMID: 27999052. doi:10.1093/jac/dkw510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。